CRE superbug linked to 2 deaths at UCLA hospital; 179 potentially exposed

[Shiloh]

Source: http://www.latimes.com/business/la-f...ry.html#page=1

Superbug linked to 2 deaths at UCLA hospital; 179 potentially exposed
By Chad Terhune
February 18, 2015

At least seven UCLA patients have been infected by a drug-resistant superbug
Two patient deaths are linked to superbug outbreak at UCLA

Nearly 180 patients at UCLA's Ronald Reagan Medical Center may have been exposed to potentially deadly bacteria from contaminated medical scopes, and two deaths have already been linked to the outbreak.

The Times has learned that the two people who died are among seven patients that UCLA found were infected by the drug-resistant superbug known as CRE ? a number that may grow as more patients get tested. The outbreak is the latest in a string of similar incidents across the country that has top health officials scrambling for a solution.

UCLA said it discovered the outbreak late last month while running tests on a patient. This week, it began to notify 179 other patients who were treated from October to January and offer them medical tests. By some estimates, if the infection spreads to a person's bloodstream, the bacteria can kill 40% to 50% of patients.

[Pathfinder]

February 18,2015

UCLA statement on notification of patients regarding endoscopic procedures

The UCLA Health System has notified more than 100 patients that they may have been infected by a “superbug” bacteria during complex endoscopic procedures that took place between October 2014 and January 2015. The patients are being offered free home testing kits that would be analyzed at UCLA.

UCLA sterilized the scopes according to the standards stipulated by the manufacturer. However, an internal investigation determined that carbapenem-resistant Enterobacteriaceae (CRE) bacteria may have been transmitted during a procedure that uses this specialized scope to diagnose and treat pancreaticobiliary diseases and may have been a contributing factor in the death of two patients. A total of seven patients were infected.

Similar CRE exposures using the same type of scope recently have been reported in other hospitals in the United States. The two scopes involved with the infection were immediately removed and UCLA is now utilizing a decontamination process that goes above and beyond manufacturer and national standards. Both the Los Angeles County Department of Health Services and the California Department of Public Health were notified as soon as the bacteria were detected.

https://www.uclahealth.org/news/ucla...pic-procedures

------------------------------------------------------------------------------------------------------------------------------------------------------
Updated Febrary 19, 2015 at 2:30 pm PT

The UCLA Health System notified 179 patients on Feb. 18 that they may have been exposed last fall to the carbapenem-resistant enterobacteriaceae (CRE) bacteria during an endoscopic procedure to diagnose and treat diseases of the liver, bile ducts and pancreas at Ronald Reagan UCLA Medical Center. A total of seven patients were infected; the infection was a contributing factor in the death of two patients.

Only patients who underwent these endoscopic procedures from October 3 to January 28 are at risk of infection. Those patients are being offered a free home testing kit for analysis at UCLA to determine if they carry the bacteria in their intestines.

UCLA followed both national guidelines and the sterilization standards stipulated by Olympus Medical Systems Group, the instrument’s manufacturer. However, an internal investigation determined in late January that CRE may have been transmitted by two of the seven Olympus scopes used by the hospital during the four-month period.

UCLA immediately began reviewing every patient record to determine which patients underwent the procedure using this type of scope between October and January. In an abundance of caution, the hospital has notified all 179 patients who were examined with one of the seven instruments during that time.

The two infected scopes were immediately removed from use for return to Olympus. UCLA currently performs a more stringent decontamination process that exceeds both the manufacturer’s standards and national guidelines. Hospital staff thoroughly clean the instrument and place it in an automated machine for disinfection. Then the instrument is sent off-site for a second sterilization process using a gas called ethylene oxide.

The Los Angeles County Department of Health and California Department of Public Health were notified as soon as the outbreak was detected. CRE exposures using the same type of scope have been reported in other U.S. hospitals. Concerned patients may contact their primary care physician or UCLA’s clinical epidemiology and infection prevention department at 310-794-0189.
Contact Information

Patient hotline: 310-794-0189

https://www.uclahealth.org/news/ucla...pic-procedures

[Pathfinder]

Design of Endoscopic Retrograde Cholangiopancreatography (ERCP) Duodenoscopes May Impede Effective Cleaning: FDA Safety Communication

Date Issued: February 19, 2015
Audience:

• Gastroenterologists
• Gastrointestinal surgeons
• Endoscopy nurses
• Staff working in endoscopy reprocessing units in health care facilities
• Infection control practitioners
• Patients considering endoscopic retrograde cholangiopancreatography (ERCP) procedures

Medical Specialties: Gastroenterology, Infection Control
Device: All ERCP endoscopes (side-viewing duodenoscopes)

Figure 1: Close-up view of an ERCP endoscope tip.

Purpose:

The FDA wants to raise awareness among health care professionals, including those working in reprocessing units in health care facilities, that the complex design of ERCP endoscopes (also called duodenoscopes) may impede effective reprocessing. Reprocessing is a detailed, multistep process to clean and disinfect or sterilize reusable devices. Recent medical publications and adverse event reports associate multidrug-resistant bacterial infections in patients who have undergone ERCP with reprocessed duodenoscopes, even when manufacturer reprocessing instructions are followed correctly. Meticulously cleaning duodenoscopes prior to high-level disinfection should reduce the risk of transmitting infection, but may not entirely eliminate it.

Summary of Problem and Scope:

More than 500,000 ERCP procedures using duodenoscopes are performed in the United States annually. The procedure is the least invasive way of draining fluids from pancreatic and biliary ducts blocked by cancerous tumors, gallstones, or other conditions. Duodenoscopes are flexible, lighted tubes that are threaded through the mouth, throat, stomach, and into the top of the small intestine (the duodenum). They contain a hollow channel that allows the injection of contrast dye or the insertion of other instruments to obtain tissue samples for biopsy or treat certain abnormalities. Unlike most other endoscopes, duodenoscopes also have a movable “elevator” mechanism at the tip. The elevator mechanism changes the angle of the accessory exiting the accessory channel, which allows the instrument to access the ducts to treat problems with fluid drainage.

Although the complex design of duodenoscopes improves the efficiency and effectiveness of ERCP, it causes challenges for cleaning and high-level disinfection. Some parts of the scopes may be extremely difficult to access and effective cleaning of all areas of the duodenoscope may not be possible. In addition, a recent FDA engineering assessment and a growing body of literature have identified design issues in duodenoscopes that complicate reprocessing of these devices. For example, one step of the manual cleaning instructions in device labeling is to brush the elevator area. However, the moving parts of the elevator mechanism contain microscopic crevices that may not be reached with a brush. Residual body fluids and organic debris may remain in these crevices after cleaning and disinfection. If these fluids contain microbial contamination, subsequent patients may be exposed to serious infections.

The FDA is closely monitoring the association between reprocessed duodenoscopes and the transmission of infectious agents, including multidrug-resistant bacterial infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE) such as Klebsiella species and Escherichia coli. In total, from January 2013 through December 2014, the FDA received 75 MDRs encompassing approximately 135 patients in the United States relating to possible microbial transmission from reprocessed duodenoscopes. It is possible that not all cases have been reported to the FDA. The agency is continuing to evaluate information about documented and potential infections from multiple sources, including Medical Device Reports (MDRs) submitted to the FDA, the medical literature, the health care community, professional medical societies, and the Centers for Disease Control and Prevention (CDC).

Recommendations for Facilities and Staff that Reprocess ERCP Duodenoscopes:

• Follow closely all manufacturer instructions for cleaning and processing.
  • The FDA recommends adherence to general endoscope reprocessing guidelines and practices established by the infection control community and endoscopy professionals, as described in the Additional Resources section, below. In addition, it is important to follow specific reprocessing instructions in the manufacturer’s labeling for each device.
  • Even though duodenoscopes are inherently difficult to reprocess, strict adherence to the manufacturer’s reprocessing instructions will minimize the risk of infection. Deviations from the manufacturer's instructions for reprocessing may contribute to contamination. The benefit of using cleaning accessories not specified in the manufacturer’s instructions, such as channel flushing aids, brushes, and cleaning agents, is not known.
• Report problems with reprocessing the device to the manufacturer and to the FDA, as described below.
• Follow these additional general best practices:
  • Meticulously clean the elevator mechanism and the recesses surrounding the elevator mechanism by hand, even when using an automated endoscope reprocessor (AER). Raise and lower the elevator throughout the manual cleaning process to allow brushing of both sides.
  • Implement a comprehensive quality control program for reprocessing duodenoscopes. Your reprocessing program should include written procedures for monitoring training and adherence to the program, and documentation of equipment tests, processes, and quality monitors used during the reprocessing procedure.
  • Refer to the Multisociety Guideline on Reprocessing Flexible Gastrointestinal Endoscopes: 2011 consensus document for evidence-based recommendations for endoscope reprocessing.

Recommendations for Health Care Providers:

• Inform patients of the benefits and risks associated with ERCP procedures.
• Discuss with your patients what they should expect following the ERCP procedure and what symptoms (such as fever or chills, chest pain, severe abdominal pain, trouble swallowing or breathing, nausea and vomiting, or black or tarry stools) should prompt additional follow-up.
• Consider taking a duodenoscope out of service until it has been verified to be free of pathogens if a patient develops an infection with a multidrug-resistant organism following ERCP, and you suspect that there may be a link between the duodenoscope and the infection.
• Submit a report to the manufacturer and to the FDA via MedWatch, as described below, if you suspect that problems with reprocessing a duodenoscope have led to patient infections.

Recommendations for Patients:

• Discuss the benefits and risks of procedures using duodenoscopes with your physician. For most patients, the benefits of ERCP outweigh the risks of infection. ERCP often treats life-threatening conditions that can lead to serious health consequences if not addressed.
• Ask your doctor what to expect following the procedure and when to seek medical attention. Following ERCP, many patients may experience mild symptoms such as a sore throat or mild abdominal discomfort. Call your doctor if, following your procedure, you have a fever or chills, or other symptoms that may be a sign of a more serious problem (such as chest pain, severe abdominal pain, trouble swallowing or breathing, nausea and vomiting, or black or tarry stools).

FDA Activities:

The FDA is actively engaged with other government agencies, including CDC, and the manufacturers of duodenoscopes used in the United States to identify the causes and risk factors for transmission of infectious agents and develop solutions to minimize patient exposure. Recent FDA activities include:

• Collaboration with CDC and the Environmental Protection Agency (EPA) to test the antibiotic-resistant organisms to assess their susceptibility to high-level disinfectants.
• Exploration, with CDC, of additional potential strategies to reduce the risk of infections, such as microbiological surveillance testing of duodenoscopes.
• Communication with international public health agencies to study the extent of the problem and identify possible solutions being considered outside the United States.
• Reviews of reprocessing validation data from each of the three manufacturers marketing duodenoscopes in the United States (FUJIFILM, Olympus, and Pentax).

The FDA continues to actively monitor this situation and will provide updates as appropriate.
Reporting Problems to the FDA:
Device manufacturers and user facilities must comply with the applicable Medical Device Reporting (MDR) regulations.
Health care personnel employed by facilities that are subject to the FDA's user facility reporting requirementsshould follow the reporting procedures established by their facilities.
Prompt reporting of adverse events can help the FDA identify and better understand the risks associated with medical devices. Health care providers should submit voluntary reports of the transmission of an infection due to an inadequately cleaned duodenoscope to the agency via the Medical Device Reporting (MDR) process.
If, after following the manufacturer’s reprocessing instructions, a health care provider suspects bacterial contamination—either because of an increase in infections after ERCP, or because of the results of bacterial surveillance culturing of duodenoscopes—we encourage the health care provider to file a voluntary report through MedWatch, the FDA Safety Information and Adverse Event Reporting program.
Additional Resources:

• American Society for Gastrointestinal Endoscopy: Multisociety Guideline on Reprocessing Flexible Gastrointestinal Endoscopes: 2011
• Society of Gastroenterology Nurses and Associates: Standards of Infection Control in Reprocessing of Flexible Gastrointestinal Endoscopes
• FDA: Reprocessing of Reusable Medical Devices
• FDA: Preventing Cross-Contamination in Endoscope Processing: FDA Safety Communication

References:
Alrabaa SF, Nguyen P, Sanderson R, et al. June 2013. Early Identification and Control of Carbapenemase-Producing Klebsiella Pneumoniae, Originating from Contaminated Endoscopic Equipment. Retrieved fromhttp://www.ncbi.nlm.nih.gov/pubmed/23171594
Aumeran C, Poincloux L, Souweine B, et al. November 2010. Multidrug-Resistant Klebsiella Pneumoniae Outbreak After Endoscopic Retrograde Cholangiopancreatography. Retrieved fromhttp://www.ncbi.nlm.nih.gov/pubmed/20725887
Epstein L, Hunter JC, Arwady MA, et al. October 2014. New Delhi Metallo-β-Lactamase–Producing Carbapenem-Resistant Escherichia Coli Associated with Exposure to Duodenoscopes. Retrieved fromhttp://jama.jamanetwork.com/article....icleid=1911326
Rutala WA and Weber DJ. October 2014. Gastrointestinal Endoscopes: A Need to Shift From Disinfection to Sterilization? Retrieved from http://jama.jamanetwork.com/article....icleid=1911309
Verfaillie C, Bruno M, Poley, JW, et al. Withdrawal of a Duodenoscope Stops Outbreak by A Vim-2 Pseudomonas Aeruginosa. [Abstract] Retrieved fromhttp://www.icaaconline.com/php/icaac...014/K-1685.htm
Contact Information:
If you have questions about this communication, please contact the Division of Industry and Consumer Education (DICE) at DICE@FDA.HHS.GOV, 800-638-2041 or 301-796-7100.

http://www.fda.gov/MedicalDevices/Sa.../ucm434871.htm

[Pathfinder]

UCLA 'Superbug' Patient to Sue Maker of Suspect Endocopes: Lawyer

BY BILL BRIGGS
...
The 18-year-old, who had to be readmitted to the Los Angeles hospital in January, was initially infected last October with a potentially deadly bacteria called carbapenem-resistant Enterobacteriaceae, or CRE, his lawyer said.

Staff at Ronald Reagan UCLA used one of the Olympus endoscopes to examine the teen's pancreas while he was suffering from pancreatitis, said Boyle, who declined to release the teen's name.

It's unclear, Boyle said, whether his client was the first UCLA patient to become infected with CRE ? a "family of germs" highly resistant to antibiotics, according to the Centers for Disease Control and Prevention.

In a previous news release, the CDC said the drug-resistant bacteria can kill up to half of all patients who become infected with it in their bloodstreams. CDC director Dr. Tom Frieden has called CRE a "nightmare bacteria."

"He went home (after the scope procedure)," Boyle said. "Then, a few days later was just feeling horribly, and went back in. They started running tests. They figured out in, at least, November that he had CRE.

"He spent 83 days in the hospital, the majority of that in the ICU. He was released but unfortunately in January he had to go back in the hospital," Boyle added. "The CRE 'superbug,' as they're calling it, attacks the immune system. So he just was suffering from an extremely weakened immune system, putting him at risk for a whole host of things."
...
First published February 20th 2015, 7:55 pm

http://www.nbcnews.com/health/health-news/ucla-superbug-patient-sue-maker-suspect-endocopes-lawyer-n309891